Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA
By Sabela Ojea
Alnylam Pharmaceuticals said that it received a positive review from the U.S. Food and Drug Administration regarding its supplemental new drug application to treat a heart disease through its Onpattro drug.
The biopharmaceutical company said 9 out of 12 members of the cardiovascular and renal drugs Advisory committee voted that the benefits of its medication outweigh its risks for the treatment of cardiomyopathy of ATTR amyloidosis.
Transthyretin amyloid cardiomyopathy is a rare but severe cause of cardiomyopathy that takes place as a result of an accumulation of the transthyretin protein.
"We look forward to continuing to work with the FDA as they complete their review of our sNDA," said Pushkal Garg, Alnylam's chief medical officer.
Earlier on Wednesday, Alnylam Pharmaceuticals shares were halted from trading while the regulatory advisory committee met to review its sNDA.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 13, 2023 17:33 ET (21:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks